Acute and Chronic immune biomarker changes during interferon/ribavirin treatment in HIV/HCV co-infected patients

Journal of Viral Hepatitis

Volumn 22, Issue 1, 2014, Pages 25-36

  Jain, M K ^a   Adams Huet, B ^b   Terekhova, D ^a   Kushner, L E ^d   Bedimo, R ^a,c   Li, X ^b   Holodniy, M ^d,e  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

^c VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^d VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiviral treatment; HCV; HIV; Immune response; Interferon

Indexed keywords

BIOLOGICAL MARKER; COLONY STIMULATING FACTOR 1; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; LEPTIN; LYMPHOTOXIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 3; PEGINTERFERON ALPHA; PLATELET DERIVED GROWTH FACTOR BB; RIBAVIRIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNINDEXED DRUG; ALPHA INTERFERON; ANTIVIRUS AGENT;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIVER BIOPSY; MALE; MIXED INFECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TREATMENT OUTCOME; TREATMENT RESPONSE; ADOLESCENT; AGED; BLOOD; COMPLICATION; CYTOCHEMISTRY; HEPACIVIRUS; HEPATITIS C, CHRONIC; IMMUNOLOGY; ISOLATION AND PURIFICATION; LIVER; MIDDLE AGED; PATHOLOGY; VIRUS LOAD; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; BIOMARKERS; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HISTOCYTOCHEMISTRY; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; LIVER; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RIBAVIRIN; VIRAL LOAD; YOUNG ADULT;

EID: 84926160614     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12226     Document Type: Article

References (50)

1. Yonkers NL, Sieg S, Rodriguez B, Anthony DD. Reduced naive CD4 T cell numbers and impaired induction of CD27 in response to T cell receptor stimulation reflect a state of immune activation in chronic hepatitis C virus infection. J Infect Dis 2011;203:635-645.
2. Gonzalez VD, Landay AL, Sandberg JK. Innate immunity and chronic immune activation in HCV/HIV-1 co-infection. Clin Immunol 2010;135:12-25.
3. Schlatzer DM, Sugalski JM, Chen Y et al. Plasma proteome analysis reveals overlapping, yet distinct mechanisms of immune activation in chronic HCV and HIV infections. J Acquir Immune Defic Syndr 2013;63:563-571.
4. Weiss G, Umlauft F, Urbanek M et al. Associations between cellular immune effector function, iron metabolism, and disease activity in patients with chronic hepatitis C virus infection. J Infect Dis 1999;180:1452-1458.
5. Mengshol JA, Golden-Mason L, Rosen HR. Mechanisms of Disease: HCV-induced liver injury. Nat Clin Pract Gastroenterol Hepatol 2007;4:622-634.
6. Rasmussen AL, Wang IM, Shuhart MC et al. Chronic immune activation is a distinguishing feature of liver and PBMC gene signatures from HCV/HIV coinfected patients and may contribute to hepatic fibrogenesis. Virology 2012;430:43-52.
7. Lewden C, May T, Rosenthal E et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: the "Mortalite 2000 and 2005" surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr 2008;48:590-598.
8. Gonzalez VD, Falconer K, Blom KG et al. High levels of chronic immune activation in the T-cell compartments of patients coinfected with hepatitis C virus and human immunodeficiency virus type 1 and on highly active antiretroviral therapy are reverted by alpha interferon and ribavirin treatment. J Virol 2009;83:11407-11411.
9. Yoneda S, Umemura T, Katsuyama Y et al. Association of serum cytokine levels with treatment response to pegylated interferon and ribavirin therapy in genotype 1 chronic hepatitis C patients. J Infect Dis 2011;203:1087-1095.
10. Akcam FZ, Tigli A, Kaya O, Ciris M, Vural H. Cytokine levels and histopathology in chronic hepatitis B and chronic hepatitis C. J Interferon Cytokine Res 2012;32:570-574.
11. Neuman MG, Benhamou JP, Malkiewicz IM et al. Kinetics of serum cytokines reflect changes in the severity of chronic hepatitis C presenting minimal fibrosis. J Viral Hepat 2002;9:134-140.
12. Valdez H, Anthony D, Farukhi F et al. Immune responses to hepatitis C and non-hepatitis C antigens in hepatitis C virus infected and HIV-1 coinfected patients. AIDS 2000;14:2239-2246.
13. Roe B, Coughlan S, Hassan J et al. Elevated serum levels of interferongamma-inducible protein-10 in patients coinfected with hepatitis C virus and HIV. J Infect Dis 2007;196:1053-1057.
14. Sitia G, De Bona A, Bagaglio S et al. Naive HIV/HCV-coinfected patients have higher intrahepatic pro-inflammatory cytokines than coinfected patients treated with antiretroviral therapy. Antivir Ther 2006;11:385-389.
15. Neumann A, Polis M, Rozenberg L et al. Differential antiviral effect of PEG-interferon-alpha-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients. AIDS 2007;21:1855-1865.
16. Azzoni L, Foulkes AS, Papasavvas E et al. Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. J Infect Dis 2013;207:213-222.
17. Jordan WC. Three open-label studies of oral interferon alpha in the treatment of HIV disease. J Natl Med Assoc 1994;86:257-262.
18. Sneller MC. Consensus symposium on combined antiviral therapy; overview of interferon and IL-2 combinations for the treatment of HIV infection. Antiviral Res 1996;29:105-109.
19. Jain MK, Yuan HJ, Adams-Huet B et al. Pegylated interferon and ribavirin promote early evolution of nonstructural 5A protein in individuals with hepatitis C who demonstrate a response to treatment. J Infect Dis 2009;200:866-876.
20. Yuan H, Adams-Huet B, Petersen T, Attar N, Lee WM, Jain MK. A single nucleotide polymorphism in IL28B affects viral evolution of hepatitis C quasispecies after pegylated interferon and ribavirin therapy. J Med Virol 2012;84:1913-1919.
21. Ludwig J, Batts KP, Moyer TP, Poterucha JJ. Advances in liver biopsy diagnosis. Mayo Clin Proc 1994;69:677-678.
22. Tilg H, Mier JW, Vogel W et al. Induction of circulating IL-1 receptor antagonist by IFN treatment. J Immunol 1993;150:4687-4692.
23. Luster AD, Ravetch JV. Biochemical characterization of a gamma interferon-inducible cytokine (IP-10). J Exp Med 1987;166:1084-1097.
24. Oshima K, Yanase N, Ibukiyama C et al. Involvement of TRAIL/TRAIL-R interaction in IFN-alpha-induced apoptosis of Daudi B lymphoma cells. Cytokine 2001;14:193-201.
25. Masia M, Robledano C, Lopez N, Escolano C, Gutierrez F. Treatment for hepatitis C virus with pegylated interferon-alpha plus ribavirin induces anti-atherogenic effects on cardiovascular risk biomarkers in HIV-infected and -uninfected patients. J Antimicrob Chemother 2011;66:1861-1868.
26. Nattermann J, Vogel M, Berg T et al. Effect of the interleukin-6 C174G gene polymorphism on treatment of acute and chronic hepatitis C in human immunodeficiency virus coinfected patients. Hepatology 2007;46:1016-1025.
27. Okada-Ban M, Thiery JP, Jouanneau J. Fibroblast growth factor-2. Int J Biochem Cell Biol 2000;32:263-267.
28. Guerret S, Desmouliere A, Chossegros P et al. Long-term administration of interferon-alpha in non-responder patients with chronic hepatitis C: follow-up of liver fibrosis over 5 years. J Viral Hepat 1999;6:125-133.
29. Schvarcz R, Glaumann H, Reichard O, Weiland O. Histological and virological long-term outcome in patients treated with interferonalpha2b and ribavirin for chronic hepatitis C. J Viral Hepat 1999;6:237-242.
30. Shiratori Y, Imazeki F, Moriyama M et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000;132:517-524.
31. Kushner LE, Wendelboe AM, Lazzeroni LC et al. Immune biomarker differences and changes comparing HCV mono-infected, HIV/HCV co-infected, and HCV spontaneously cleared patients. PLoS ONE 2013;8:e60387.
32. Gieling RG, Wallace K, Han YP. Interleukin-1 participates in the progression from liver injury to fibrosis. Am J Physiol Gastrointest Liver Physiol 2009;296:G1324-G1331.
33. Dominguez M, Miquel R, Colmenero J et al. Hepatic expression of CXC chemokines predicts portal hypertension and survival in patients with alcoholic hepatitis. Gastroenterology 2009;136:1639-1650.
34. Knight B, Lim R, Yeoh GC, Olynyk JK. Interferon-gamma exacerbates liver damage, the hepatic progenitor cell response and fibrosis in a mouse model of chronic liver injury. J Hepatol 2007;47:826-833.
35. Vargas A, Berenguer J, Ryan P et al. Plasma interferon-gammainducible protein-10 can predict virologic response to hepatitis C virus therapy in HIV/HCV-coinfected patients with HCV genotype 1. J Acquir Immune Defic Syndr 2010;54:219-220.
36. Anatol P, Robert F, Danuta P. Effect of interferon alpha2b plus ribavirin treatment on selected growth factors in respect to inflammation and fibrosis in chronic hepatitis C. World J Gastroenterol 2005;11:1854-1858.
37. Ray S, Broor SL, Vaishnav Y et al. Transforming growth factor beta in hepatitis C virus infection: in vivo and in vitro findings. J Gastroenterol Hepatol 2003;18:393-403.
38. Castilla A, Prieto J, Fausto N. Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy. N Engl J Med 1991;324:933-940.
39. Hickman IJ, Powell EE, Prins JB et al. In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy. J Hepatol 2003;39:1042-1048.
40. Romero-Gomez M, Del Mar Viloria M, Andrade RJ et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005;128:636-41.
41. Vargas A, Berenguer J, Catalan P et al. Association between plasma levels of eotaxin (CCL-11) and treatment response to interferon-alpha and ribavirin in HIV/HCV co-infected patients. J Antimicrob Chemother 2010;65:303-306.
42. Zekri AR, Bahnassy AA, Mohamed WS et al. Dynamic interplay between CXCL levels in chronic hepatitis C patients treated by interferon. Virol J. 2013;10:218.
43. Panella C, Francavilla A, Conte D, Tatulli I, Rubini F. Clinical and histological evaluation of interferon alfa-2b in the treatment of chronic hepatitis C. Gut 1993;2(Suppl):S127.
44. David E, Pucci A, Palladin D et al. Histologic changes in liver biopsy specimens produced by recombinant interferon alpha-2b therapy for chronic non-A, non-B viral hepatitis. A randomized controlled trial. Am J Clin Pathol 1992;98:397-401.
45. Filippini P, Coppola N, Pisapia R et al. Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy. AIDS 2006;20:1253-1260.
46. Okajima A, Miyazawa K, Naitoh Y, Inoue K, Kitamura N. Induction of hepatocyte growth factor activator messenger RNA in the liver following tissue injury and acute inflammation. Hepatology 1997;25:97-102.
47. Benhamou Y, Bochet M, Di Martino V et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999;30:1054-1058.
48. Graham CS, Wells A, Liu T et al. Antigen-specific immune responses and liver histology in HIV and hepatitis C coinfection. AIDS 2005;19:767-773.
49. Sobesky R, Mathurin P, Charlotte F et al. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group. Gastroenterology 1999;116:378-386.
50. Monto A, Kakar S, Dove LM, Bostrom A, Miller EL, Wright TL. Contributions to hepatic fibrosis in HIV-HCV coinfected and HCV monoinfected patients. Am J Gastroenterol 2006;101:1509-1515.